Psychiatric opinion and antipsychotic selection in the management of schizophrenia

Psychiatric Services

Volumn 59, Issue 5, 2008, Pages 561-565

  Arbuckle, Melissa R ^a,b   Gameroff, Marc J ^a,b   Marcus, Steven C ^c   West, Joyce C ^d   Wilk, Joshua ^e   Olfson, Mark ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d AMERICAN PSYCHIATRIC ASSOCIATION   (United States)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT;

ARTICLE; DRUG INDUSTRY; HEALTH CARE QUALITY; MEDICAL DECISION MAKING; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; PSYCHIATRIST; RISK FACTOR; SCHIZOPHRENIA; TREATMENT PLANNING;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; EXPERT TESTIMONY; FEMALE; HUMANS; MALE; PSYCHIATRY; QUESTIONNAIRES; SCHIZOPHRENIA; WORKPLACE;

EID: 46849107455     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.59.5.561     Document Type: Article

References (17)

1. Lehman AF, Lieberman JA, Dixon LB, et al: Practice guideline for the treatment of patients with schizophrenia, 2nd ed. American Journal of Psychiatry 161(suppl 2):1-56, 2004
2. Lehman AF, Kreyenbuhl J, Buchanan RW, et al: The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophrenia Bulletin 30:193-217, 2004
3. Miller AL, Hall CS, Buchanan RW, et al: The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. Journal of Clinical Psychiatry 65:500-508, 2004
4. Kane JM, Leucht S, Carpenter D, et al: Expert Consensus Guideline Series: optimizing pharmacologic treatment of psychotic disorders. Journal of Clinical Psychiatry 64 (suppl 12):5-19, 2003
5. Jin H, Meyer JM, Jeste DV: Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophrenia Research 71:195-212, 2004
6. Duggan M: Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. Journal of Health Economics 24:1-31, 2005
7. Rosenheck R, Perlick D, Bingham S, et al: Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA 290:2693-2702, 2003
8. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
9. Jones PB, Barnes TRE, Davies L, et al: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry 63:1079-1087, 2006
10. Kreyenbuhl J, Marcus SC, West JC, et al: Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatric Services 58:983-990, 2007
11. Tandon R, Fleischhacker WW: Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophrenia Research 79:145-155, 2005
12. Chakos M, Lieberman J, Hoffman E, et al: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 158:518-526, 2001
13. Peay MY, Peay ER: Patterns of preference for information sources in the adoption of new drugs by specialists. Social Science and Medicine 31:467-476, 1990
14. Avorn J, Chen M, Harely R: Scientific versus commercial sources of influence on the prescribing behavior of physicians. American Journal of Psychiatry 73:4-8, 1982
15. Wazana A: Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 283:373-381, 2000
16. Studdert DM, Mello MM, Brennan TA: Financial conflicts of interest in physicians' relationships with the pharmaceutical industry: self-regulation in the shadow of federal prosecution. New England Journal of Medicine 351:1891-1900, 2004
17. Choudhry NK, Stelfox HT, Detsky AS: Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287:612-617, 2002